Grdn

**GRDN's Recent Performance and Analyst Ratings**:

1. **Market Debut and Valuation**:
- Guardian Pharmacy Services Inc. (GRDN) successfully completed its initial public offering (IPO) on September 25, 2024, raising $112 million, which values the company at approximately $852 million to $869.3 million, depending on the source.
- The company’s shares began trading on the New York Stock Exchange (NYSE) under the ticker symbol "GRDN" at $14 per share, the lower end of the price range.
- On October 14, 2024, the closing price for GRDN was $17.15.

2. **Analyst Ratings and Price Targets**:
- As of October 11, 2024, the consensus rating for GRDN is not available, and there are no analyst price targets set.
- This lack of coverage could be due to the company's recent IPO or the specific focus of analysts, which might not have included GRDN at this time.

3. **Financial Metrics**:
- For the full-year 2023, Guardian Pharmacy's revenue rose to $1.05 billion, compared with $908.9 million a year earlier.
- The company's net profit for 2023 was $37.7 million, down from $49.7 million in 2022.
- The company's shares are positioned to leverage the recovery in investor appetite for IPOs, supported by expectations of monetary policy easing and a soft economic landing.
4. **Market Position and Outlook**:
- Guardian Pharmacy Services operates 50 pharmacies, serving approximately 174,000 residents as of June 30, 2024.
- The company's revenue has been primarily driven by residents in assisted living facilities, behavioral health facilities, and group homes, with a smaller portion from skilled nursing facilities.
- The company's relative strength (RS) rating improved from 69 to 86, indicating enhanced market leadership potential.
- Despite recent improvements, the company's earnings per share (EPS) growth fell from 133% to -44% in the last quarter, while sales growth increased from 11% to 18%.

In conclusion, GRDN has shown resilience in its financial performance and market positioning, which could be reflected in its recent IPO success and market valuation. However, the lack of current analyst ratings and price targets may indicate a need for further market engagement or specific sector focus by analysts. Investors should consider the company's strong revenue growth, particularly in its niche service areas, and the broader market recovery trends that have supported its IPO.